On January 27, 2006, Pfizer Inc. received word from the FDA that its inhalable insulin Exubera was granted approval. It is the first inhaled form of insulin and the first insulin option that does not need to be administered by injection in the United States.
In a news release, Pfizer stated that, in clinical trials, Exubera was found to be as effective as short-acting insulin injections, and to significantly improve blood sugar control when added to diabetes pills.
Exubera is expected to be available for insulin-using patients by mid 2006. Diabetes Health will do a comprehensive article about Exubera in next month’s issue.
Source: Pfizer, Inc. January 27, 2006